Prophylactic OKT3: practical considerations for the prevention of first-dose reactions.
Doutrelepont
J M
JM
Department of Nephrology, Hôpital Erasme, Université Libre de Bruxelles, Belgium.
Abramowicz
D
D
Borre
B
B
Lemoine
A
A
De Pauw
L
L
Kinnaert
P
P
Vereerstraeten
P
P
Vanherweghem
J L
JL
Goldman
M
M
D001379:Azathioprine / Q000627:therapeutic use*; D006801:Humans; D007432:Intraoperative Period; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011184:Postoperative Period; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D001379:Azathioprine; D008775:Methylprednisolone